Topics

Mercia invests £2.0 million in transdermal drug delivery specialist, Medherant

10:15 EDT 21 May 2019 | Sciad Newswire

Coventry, UK, 21st May 2019 / Sciad NewswireMedherant Limited (“Medherant”), the clinical-stage developer of innovative transdermal delivery products for pain and CNS diseases using its unique TEPI Patch® technology, has today announced a new £2 million investment.

Original Article: Mercia invests £2.0 million in transdermal drug delivery specialist, Medherant

NEXT ARTICLE

More From BioPortfolio on "Mercia invests £2.0 million in transdermal drug delivery specialist, Medherant"

Quick Search

Relevant Topics

Anesthesiology
An anesthesiologist (US English) or anaesthetist (British English) is a physician trained in anesthesia and perioperative medicine. Anesthesiologists are physicians who provide medical care to patients in a wide variety of (usually acute) situations. ...

Neurology - Central Nervous System (CNS)
Alzheimer's Disease Anesthesia Anxiety Disorders Autism Bipolar Disorders Dementia Epilepsy Multiple Sclerosis (MS) Neurology Pain Parkinson's Disease Sleep Disorders Neurology is the branch of me...